Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182(2):459–65.
Article
PubMed
CAS
Google Scholar
Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734–6.
Article
PubMed
CAS
Google Scholar
Selby MJ, et al. Preclinical development of Ipilimumab and Nivolumab combination immunotherapy: mouse tumor models, in vitro functional studies, and Cynomolgus macaque toxicology. PLoS One. 2016;11(9):e0161779.
Article
PubMed
PubMed Central
CAS
Google Scholar
Hodi FS, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 2008;105(8):3005–10.
Article
PubMed
PubMed Central
Google Scholar
Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.
Article
PubMed
PubMed Central
CAS
Google Scholar
Robert C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–26.
Article
PubMed
CAS
Google Scholar
Schadendorf D, et al. Pooled analysis of long-term survival data from phase II and phase III trials of Ipilimumab in Unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889–94.
Article
PubMed
PubMed Central
CAS
Google Scholar
Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist. 2007;12(7):864–72.
Article
PubMed
CAS
Google Scholar
Larkin J, et al. Neurologic serious adverse events associated with Nivolumab plus Ipilimumab or Nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist. 2017;22(6):709–18.
Article
PubMed
PubMed Central
CAS
Google Scholar
Ibrahim R, Berman D, de Pril V, et al. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. J Clin Oncol. 2011;29(15_Suppl):8583.
Article
Google Scholar
Iwama S, et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014;6(230):230ra45.
Article
PubMed
CAS
Google Scholar
Postow MA, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–17.
Article
PubMed
PubMed Central
Google Scholar
Linardou H, Gogas H. Toxicity management of immunotherapy for patients with metastatic melanoma. Ann Transl Med. 2016;4(14):272.
Article
PubMed
PubMed Central
CAS
Google Scholar
Beck KE, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006;24(15):2283–9.
Article
PubMed
PubMed Central
CAS
Google Scholar
Johnston RL, et al. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci. 2009;54(11):2538–40.
Article
PubMed
CAS
Google Scholar
Eggermont AM, et al. Prolonged survival in stage III melanoma with Ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845–55.
Article
PubMed
PubMed Central
CAS
Google Scholar
Brahmer JR, et al. Management of Immune-Related Adverse Events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714–68.
Article
PubMed
Google Scholar
Bompaire F, et al. Severe meningo-radiculo-neuritis associated with ipilimumab. Investig New Drugs. 2012;30(6):2407–10.
Article
Google Scholar
Conry RM, Sullivan JC, Nabors LB 3rd. Ipilimumab-induced encephalopathy with a reversible splenial lesion. Cancer Immunol Res. 2015;3(6):598–601.
Article
PubMed
Google Scholar
Williams TJ, et al. Association of Autoimmune Encephalitis with Combined Immune Checkpoint Inhibitor Treatment for metastatic Cancer. JAMA Neurol. 2016;73(8):928–33.
Article
PubMed
Google Scholar
Bot I, et al. Neurological immune-related adverse events of ipilimumab. Pract Neurol. 2013;13(4):278–80.
Article
PubMed
Google Scholar
Naito T, et al. Acute cerebellitis after administration of nivolumab and ipilimumab for small cell lung cancer. Neurol Sci. 2018; https://doi.org/10.1007/s10072-018-3465-4.
Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann Oncol. 2011;22(4):991–3.
Article
PubMed
CAS
Google Scholar
Johnson DB, et al. Myasthenia gravis induced by Ipilimumab in patients with metastatic melanoma. J Clin Oncol. 2015;33(33):e122–4.
Article
PubMed
PubMed Central
Google Scholar
Derle E, Benli S. Ipilimumab treatment associated with myasthenic crises and unfavorable disease course. Neurol Sci. 2018; https://doi.org/10.1007/s10072-018-3471-6.
Montes V, et al. Myasthenia gravis induced by Ipilimumab in a patient with metastatic melanoma. Front Neurol. 2018;9:150.
Article
PubMed
PubMed Central
Google Scholar
Chen JH, et al. Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: a case report and literature review. Medicine (Baltimore). 2017;96(50):e9262.
Article
Google Scholar
Ruff MW, Mauermann ML. The Mayo Clinic experience with the neurological complications of the CTLA-4 inhibitor Ipilimumab. Neurologist. 2018;23(3):98–9.
Article
PubMed
Google Scholar
Liao B, et al. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-Oncology. 2014;16(4):589–93.
Article
PubMed
PubMed Central
CAS
Google Scholar
Graus F, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391–404.
Article
PubMed
PubMed Central
Google Scholar
Abdallah AO, et al. Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: a case report and review of literature. J Oncol Pharm Pract. 2016;22(3):537–42.
Article
PubMed
CAS
Google Scholar
Mandel JJ, et al. Lambrolizumab induced central nervous system (CNS) toxicity. J Neurol Sci. 2014;344(1–2):229–31.
Article
PubMed
PubMed Central
CAS
Google Scholar
Arriola E, et al. Infliximab for IPILIMUMAB-related colitis-letter. Clin Cancer Res. 2015;21(24):5642–3.
Article
PubMed
Google Scholar
Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2(10):1346–53.
Article
PubMed
Google Scholar
Thaipisuttikul I, Chapman P, Avila EK. Peripheral neuropathy associated with ipilimumab: a report of 2 cases. J Immunother. 2015;38(2):77–9.
Article
PubMed
PubMed Central
Google Scholar
Simpson TR, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 2013;210(9):1695–710.
Article
PubMed
PubMed Central
CAS
Google Scholar
Romano E, et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci U S A. 2015;112(19):6140–5.
Article
PubMed
PubMed Central
CAS
Google Scholar
Johnson DB, et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun. 2016;7:10582.
Article
PubMed
PubMed Central
CAS
Google Scholar
Jin PP, et al. Human leukocyte antigen DQB1 (HLA-DQB1) polymorphisms and the risk for Guillain-Barre syndrome: a systematic review and meta-analysis. PLoS One. 2015;10(7):e0131374.
Article
PubMed
PubMed Central
CAS
Google Scholar
Schirmer L, et al. Higher frequencies of HLA DQB1*05:01 and anti-glycosphingolipid antibodies in a cluster of severe Guillain-Barre syndrome. J Neurol. 2016;263(10):2105–13.
Article
PubMed
CAS
Google Scholar
Dubin K, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016;7:10391.
Article
PubMed
PubMed Central
CAS
Google Scholar
Chaput N, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28(6):1368–79.
Article
PubMed
CAS
Google Scholar
Wang YN, et al. Controlling of glutamate release by neuregulin3 via inhibiting the assembly of the SNARE complex. Proc Natl Acad Sci U S A. 2018;115(10):2508–13.
Article
PubMed
CAS
PubMed Central
Google Scholar
Spain L, et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single Centre experience and review of the literature. Ann Oncol. 2017;28(2):377–85.
PubMed
CAS
Google Scholar